Deborah Doss, BSN, RN
Articles
Tailoring Treatment for Multiple Myeloma Patients With Relapsed and Refractory Disease
Paul G. Richardson, MD;Jacob Laubach, MD;Constantine S. Mitsiades, MD, PhD;Robert L. Schlossman, MD;Deborah Doss, BSN, RN;Kathleen Colson, RN;Mary L. Mckenney, NP;Kimberly Noonan, NP;Irene M. Ghobrial, MD;Nikhil C. Munshi, MD;Kenneth C. Anderson, MD
March 16th 2010Responses to treatment of relapsed and refractory multiple myeloma are characteristically short, and median survival is as brief as 6 months. Although prognostic factors in the context of relapsed and refractory disease require further characterization, high-risk patients include those with certain cytogenetic abnormalities, high β2-microglobulin, and low serum albumin.
Latest Updated Articles
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: August 26th 2011 | Updated: December 22nd 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: October 14th 2013 | Updated: December 22nd 2024
A 51-Year-Old Patient Develops Scaly Plaque on the Right Foot
